The combination of hydroxyurea and leucapheresis in the treatment of chronic myeloid leukaemia in pregnancy.
Treatment of malignancy during pregnancy is difficult because of the potential teratogenicity of chemotherapeutic agents. Leucapheresis was employed in the initial management of a pregnant patient with chronic myeloid leukaemia. It was subsequently replaced with oral hydroxyurea during the second trimester. Successful delivery of a live male infant was achieved and the child has normal growth and development to date.
Fitzgerald
J M
JM
Department of Haematology, St. James's Hospital, Dublin, Republic of Ireland.
McCann
S R
SR
D000328:Adult; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use; D015994:Incidence; D007231:Infant, Newborn; D007370:Interferon Type I / Q000627:therapeutic use; D007937:Leukapheresis; D007938:Leukemia / Q000453:epidemiology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy*; D011256:Pregnancy Outcome; D011994:Recombinant Proteins
D007155:Immunologic Factors; D007370:Interferon Type I; D011994:Recombinant Proteins; D006918:Hydroxyurea